OncoMatch/GIST (Gastrointestinal Stromal Tumor)/KIT
GIST (Gastrointestinal Stromal Tumor)KIT Clinical Trials
KIT mutations — predominantly exon 11 deletions and exon 9 insertions — are present in approximately 70–75% of GIST and are the primary therapeutic target. Imatinib is first-line standard; sunitinib, regorafenib, and ripretinib address resistance. Avapritinib is approved for PDGFRA D842V mutations. Trials investigate ripretinib switch maintenance, novel KIT inhibitors for exon 17/18 resistance mutations, and combination strategies for KIT-mutant GIST with secondary resistance.
Top recruiting KIT GIST (Gastrointestinal Stromal Tumor) trials
Ranked by phase and US site count. See all 11 trials matched to your profile →
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Deciphera Pharmaceuticals, LLC
Imatinib TDM in GIST
Reema A. Patel
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
First Affiliated Hospital of Zhejiang University
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
Centre Leon Berard
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Asan Medical Center
Browse other molecular targets with active GIST (Gastrointestinal Stromal Tumor) trials.